



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 29 2002

TECH CENTER 1600/2900

Attorney Docket No.: DEX-0196

Inventors: Salceda et al.

Serial No.: 09/807,201

Filing Date: April 25, 2001

Examiner: Davis, Minh Tam B

Group Art Unit: 1642

Title: Method of Diagnosing, Monitoring,
Staging, Imaging and Treating Prostate
Cancer

"Express Mail" Label No. EV215113446US

Date of Deposit: November 22, 2002

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
U.S. Patent and Trademark Office, PO Box 2327,
Arlington, VA 22202

By

Kathleen A. Tyrrell
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

U.S. Patent and Trademark Office
BOX Sequence, P.O. Box 2327
Arlington, VA 22202


Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR § 1.821 THROUGH 1.825**

- () I hereby state, in accordance with the requirements of **37 C.F.R. §1.821(f)**, that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and **(e)**, respectively are the same.
- () I hereby state that the submission filed in accordance with **37 CFR §1.821(g)** does not include new matter.

- () I hereby state that the submission filed in accordance with **37 CFR §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- (XX) I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include a new matter.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing submitted herewith.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: **November 22, 2002**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

NOV 22 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0196

Inventors: Salceda et al.

Serial No.: 09/807,201

Filing Date: April 25, 2001

Examiner: Davis, Minh Tam B

Group Art Unit: 1642

Title: Method of Diagnosing, Monitoring,
Staging, Imaging and Treating Prostate
Cancer

"Express Mail" Label No. EV215113446US
Date of Deposit: November 22, 2002

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
U.S. Patent and Trademark Office, P.O. Box 2327,
Arlington, VA 22202
By Kathleen A. Tyrrell
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

U.S. Patent and Trademark Office
BOX Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

RESPONSE TO NOTICE TO COMPLY

In response to the "Notice to Comply" dated October 22,
2002, a response to which is due November 22, 2002, enclosed
herewith is:

RECEIVED

NOV 29 2002

TECH CENTER 1600/2900


11-26-02

1642

- (XX) Amendment under 1.825;
- (XX) Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
- (XX) Substitute pages of the Sequence Listing;
- (XX) Substitute copy of the computer readable form of Sequence Listing;
- (XX) Copy of Notice to Comply;
- () Petition for Three (3) Month Extension of Time;
- () Other: _____.

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 50-1619. This sheet is attached in duplicate.

Respectfully submitted,




Kathleen A. Tyrrell
Registration No. 38,350

Date: November 22, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Application No.: 0970720

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE